Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.53 |
| ▸ | HTR2C | P28335 | 9/20 | 0.53 |
| ▸ | HTR2B | P41595 | 9/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193036 | 0.89 | HTR2A (0.52) | HTR2AHTR2CHTR2B | |
| SCHEMBL1621309 | 0.86 | HTR2C (0.42) | HTR2AHTR2CCNR1CNR2KDM1A | |
| SCHEMBL1622212 | 0.85 | CNR1 (0.43) | HTR2AHTR2CHTR2BCNR1CNR2 | |
| SCHEMBL1622444 | 0.85 | CNR1 (0.42) | HTR2AHTR2CHTR2BGRIA1CNR1 | |
| SCHEMBL1622909 | 0.82 | CNR1 (0.39) | CNR1CNR2KDM1AMMP13P2RX7 | |
| SCHEMBL27013403 | 0.81 | PARP1 (0.39) | HTR2AHTR2CHTR2BCNR1CNR2 | |
| SCHEMBL27013367 | 0.80 | PARP1 (0.43) | CNR1CNR2KDM1AGRM5GRM1 | |
| SCHEMBL183689 | 0.80 | HTR2C (0.66) | HTR2AHTR2CHTR2B | |
| SCHEMBL1261952 | 0.80 | PARP1 (0.42) | CNR1CNR2KDM1AGRM5GRM1 | |
| SCHEMBL1622736 | 0.79 | SPR (0.46) | HTR2CCNR1CNR2KDM1AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618288-B2 | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-31 | — | — | US | disclosed |
| EP-1928461-B1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-04 | — | — | EP | disclosed |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-21 | — | — | US | disclosed |
| US-7598255-B2 | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-06 | — | — | US | disclosed |
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR5A, HTR6 | HTR2A 4/4885HTR2C 11/4885HTR2B 10/4885 |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR5A, HTR6 | HTR2A 4/4885HTR2C 11/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.